AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01528787
Drug: AR-13324 Ophthalmic Solution 0.02%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered to study eye, QD AM for 7 days
Trial: NCT01528787
Drug: AR-13324 Ophthalmic Solution 0.04%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered to study eye, QD AM for 7 days
Trial: NCT00849667
Drug: Taxane
RxNorm normalized name: Taxanes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane (Paclitaxel or Docetaxel) IV infusion.
Trial: NCT00851890
Drug: ABT-333
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg capsules
Trial: NCT04171505
Drug: HPV vaccine
RxNorm normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: . Patients diagnosed with HSIL / CIN 2+ who met the inclusion criteria were submitted to cervical conization and subsequently enrolled in the study after signing the informed consent, approved by ethics commission.~We will take into account the date of administration of the first dose of vaccine. The types of vaccines administered can be: Bivalent vaccine (includes genotypes 16/18), Tetravalent (includeds genotypes 6, 11, 16 and 18) both funded in the region in different years, or not funded (Nonavalent vaccine; includes genotypes: 6, 11, 16, 18, 31, 33, 45, 52 and 58). To define the time of vaccination around the conization date, the administration of the first dose of vaccine will be taken into account.
Trial: NCT02214901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03954834
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03008070
Drug: IVA337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200mg
Trial: NCT03008070
Drug: IVA337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800mg
Trial: NCT03008070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match
Trial: NCT00556439
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo abatacept infusions will be given monthly after random assignment at Month 3.
Trial: NCT04368377
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75mg daily for 30 days.
Trial: NCT04554732
Drug: Keratinocyte growth factor
RxNorm normalized name: Keratinocyte growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the end of 4 cycles of chemotherapy, primary efficacy end point data will be collected. After 20 evaluable subjects if ≥ 4 responses were noted, part 2 of the study will be activated. The decision rule is based on the lower bound of a one-sided 95% confidence interval; at least 4 out of 20 patients with response results in a lower bound greater than 5% success. The proportion with success and the lower bound of a one-sided exact confidence interval will be computed.
Trial: NCT01840813
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a placebo group
Trial: NCT01543919
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
Trial: NCT02128633
Drug: placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
Trial: NCT02128633
Drug: Fluoride neutral NaF gel 2 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The product had similar appearance and viscosity than others.
Trial: NCT01948973
Drug: Suprasensory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The stimulation is here set suprasensory
Trial: NCT02532647
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00367081
Drug: TMX-SMX (Bactrim(R))
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03929718
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: receive spironolactone treatment after CTI ablation
Trial: NCT03929718
Drug: No Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: no spironolactone treatment
Trial: NCT04446312
Drug: Bowel Prep
RxNorm normalized name: Suprep Bowel Prep Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally ingested liquid bowel preparation
Trial: NCT01082081
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01163396
Drug: 5-fluorouracil/leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02662426
Drug: Lingdancao granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 packs per time (3g/pack), three times per day
Trial: NCT02662426
Drug: analogous Lingdancao granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 packs per time, three times per day
Trial: NCT01043744
Drug: Artemether-Lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of:~* 1 tablet (for patients weighing 5-14 kg)~* 2 tablets (for patients weighing 15-24 kg)
Trial: NCT01189344
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 µg of oral levothyroxine(LT4. Blood samples were collected before and after LT4 administration
Trial: NCT01202890
Drug: Revlimid, Doxil, Avastin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
Trial: NCT02377414
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as a clear, colorless IV solution for infusion with a unit dose strength of 0.9% sodium chloride (NaCl) normal saline
Trial: NCT01218217
Drug: SQ109
RxNorm normalized name: SQ109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ109 150 mg tablet
Trial: NCT01539447
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: • Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
Trial: NCT01539447
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: • Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
Trial: NCT00936663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
Trial: NCT00269113
Drug: Standard chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00918606
Drug: LIPO-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIPO-102
Trial: NCT00443703
Drug: MK0518 (raltegravir)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
Trial: NCT00443703
Drug: Comparator: KALETRA™ (lopinavir (+) ritonavir )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment.
Trial: NCT00443703
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
Trial: NCT00443703
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.
Trial: NCT05140772
Drug: Dipeptiven
RxNorm normalized name: palmitoyl dipeptide-7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration daily for 7 days
Trial: NCT01761214
Drug: Fluroquinolones
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis
Trial: NCT01761214
Drug: Beta-lactamase inhibitor
RxNorm normalized name: Beta-lactamase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis.
Trial: NCT03636347
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily administration
Trial: NCT05140772
Drug: normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration daily for 7 days
Trial: NCT00144209
Drug: levodopa in combination with benserazide
RxNorm normalized name: benserazide / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04317339
Drug: Zhigancao Tang placebo granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhigancao Tang placebo: Dissolve Zhigancao Tang placebo granule in 200ml hot water, twice a day,12 weeks, oral.~Standard heart failure treatment，including ACEI/ARB/ARNI, aldosterone antagonists, beta blockers, nitrate esters and diuretics as needed.
Trial: NCT02869321
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02869321
Drug: Fentanyl placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02155101
Drug: ART with 2 NRTIs plus LPV/r (or ATV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.
Trial: NCT01172444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppository, Once Daily, Per Rectal for 6 Weeks
Trial: NCT00666081
Drug: GSK690693
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously at a concentration between 0.1 - 4.8 mg/mL by slow infusion over 4 h.
Trial: NCT00014274
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03134391
Drug: Vapocoolant spray, EMLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects were given vapocoolant spray to reduce pain from spinal injection; subjects were given EMLA to reduce pain from spinal injection
Trial: NCT01986894
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of Placebo
Trial: NCT01957293
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration
Trial: NCT01309204
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used as a placebo for masking purposes
Trial: NCT02786212
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02026947
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00078806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection twice a week
Trial: NCT00110994
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 tablets, po (per os) bid (twice daily) Study days 1-21
Trial: NCT06160401
Drug: Singletine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Singletine orally administered
Trial: NCT06160401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally administered
Trial: NCT02002702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02178800
Drug: GSK1265744 Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-mg tablets, taken orally
Trial: NCT02178800
Drug: Injectable GSK1265744
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: 800-mg injection, administered as two 400-mg intramuscular (IM) gluteal injections~Cohort 2: 600-mg injection, administered as one IM gluteal injection
Trial: NCT02178800
Drug: Placebo for GSK1265744 Tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken orally
Trial: NCT02178800
Drug: Injectable Placebo for GSK1265744
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohort 1: Sodium Chloride for Injection USP, 0.9%; administered as two 400-mg IM gluteal injections~Cohort 2: Sodium Chloride for Injection USP, 0.9%; administered as one 600-mg IM gluteal injection
Trial: NCT03338400
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to normal saline will receive 2ml of Normal saline at the time of induction.
Trial: NCT01558284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04272567
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous with subarachnoid block, a bolus of 6μg norepinephrine was given followed by different infusion dose of norepinephrine.
Trial: NCT04683406
Drug: ZSP1273 600 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 200-mg tablet taken orally
Trial: NCT04683406
Drug: Placebo to ZSP1273
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching ZSP1273 600 mg
Trial: NCT02969265
Drug: TCV-116CCB
RxNorm normalized name: Typhoid conjugate vaccine (TCV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCV-116CCB Tablets
Trial: NCT02969265
Drug: TCV-116CCB Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCV-116CCB 8/5 mg placebo-matching tablets
Trial: NCT04258462
Drug: Hyperpolarized 13C,15N2-urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03544905
Drug: CYH33 for tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg; 5mg; 10mg; 20mg; 30mg; 50mg; 75mg; 100mg; 130mg; 160mg; 200mg; 240mgBID or QD(Decided by SMC accroding to the safty and PK data)
Trial: NCT00602355
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants taking the placebo will follow the same titration schedule as those taking sertraline. In addition, the participates will receive the same specific mother-crafting techniques as those taking sertraline.
Trial: NCT03275090
Drug: Smoflipid ®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01789086
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
Trial: NCT02872597
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
Trial: NCT03723980
Drug: Calcium Hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: it is a synthetic antimicrobial intracanal medicament and gold standard to which other medicaments are being compared. approximately 150 mg of calcium hydroxide paste will be inserted in the root canal. it will be inserted only once and will remain in root canals for 4 days.
Trial: NCT00735553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two placebo capsules orally daily for up to four months
Trial: NCT04512001
Drug: MSB11456
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive MSB11456 subcutaneously, once a week.
Trial: NCT01431898
Drug: Placebo to Match GS-9669 tablet
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03101189
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule
Trial: NCT02820844
Drug: GSK1358820
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams \[mg\]), and human serum albumin (0.5 mg). 10 mL of the drug will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
Trial: NCT02820844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection is made up of sodium chloride (0.9 mg). 10 mL of the injection will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 cm apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
Trial: NCT02820844
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will use prophylactic antibiotic therapy approved for the indication of UTIs, at the discretion of the investigator, with the exception of those in the class of aminoglycosides. The therapy will begin 1 to 3 days prior to the administration of study treatment, and continue for 1 to 3 days following the treatment.
Trial: NCT05072054
Drug: Rosuvastatin Oral Tablet
RxNorm normalized name: rosuvastatin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg
Trial: NCT01101893
Drug: GSK2248761
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2248761 200mg q24h x 5 days (Reference Treatment)
Trial: NCT00804895
Drug: PROAMP, subcutaneous serum physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.
Trial: NCT02402530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered as intravenous infusion.
Trial: NCT03400046
Drug: Nutritional Product Supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with chronic intestinal failure were administered nutritional support including enteral and parenteral nutrition.
Trial: NCT00776542
Drug: Minocycline 100mg Tablets
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03040089
Drug: Neoquine Cream 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% hydroquinone cream
Trial: NCT02176200
Drug: Berodual® Respimat®, low inspiratory flow rate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02176200
Drug: Berodual® Respimat®, medium inspiratory flow rate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02176200
Drug: Berodual® Respimat®, high inspiratory flow rate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02176200
Drug: Berodual® HFA-MDI, low inspiratory flow rate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02176200
Drug: Berodual® HFA-MDI, medium inspiratory flow rate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02176200
Drug: Berodual® HFA-MDI, high inspiratory flow rate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02340169
Drug: Topicort® (desoximetasone) Topical Spray, 0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topicort® (desoximetasone) Topical Spray, 0.25% applied to affected areas twice a day for 28 days
Trial: NCT02059564
Drug: HM11260C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doses of 6 mg, 16 mg
Trial: NCT02059564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution
Trial: NCT02826408
Drug: Pacebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparison to active treatment
Trial: NCT01882387
Drug: TXA127
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection, 300mcg/kg/day for 28 days
Trial: NCT00245453
Drug: azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
Trial: NCT00245453
Drug: telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg tablets; 2 tablets once daily (QD) for 5 days
Trial: NCT00245453
Drug: Clarythromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg extended release tablets; 2 tablets QD for 7 days
Trial: NCT01689987
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00648258
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 10 mg tablet by mouth once daily for 6 weeks
Trial: NCT00648258
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen 500 mg capsule by mouth twice daily for 6 weeks